{"entity":{"id":"nct06712680","kind":"trial","name":"A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes","aka":[],"tldr":"A phase 1/2 trial of Test Product HYP-6589 in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.","summary":"A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes is a phase 1/2 interventional study registered as NCT06712680 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 115 participants planned, started 2024-11-27 and due to reach its primary completion in 2028-04-10. Interventions recorded: Test Product HYP-6589.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06712680","url":"https://clinicaltrials.gov/study/NCT06712680"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sichuan-huiyu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06712680","phase":"1/2","setting":"A Phase I/II , Open-label, Multi-center, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HYP-6589 Monotherapy in Advanced Solid Tumors and Combination With Tyrosine Kinase Inhibitors in Patients With Advanced NSCLC With Target-driven Gene Positivity","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","participation":[{"nct":"NCT06712680","source":"https://clinicaltrials.gov/study/NCT06712680","fetchedAt":"2026-10-07T16:54:56.691Z","studySha256":"35522152b9ee7a4ea3be59b3d1803b24651e6fd3144388c4c4a4141f47e44d62","overallStatus":"RECRUITING","lastUpdatePosted":"2025-12-23","leadSponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":115,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-11-27","startedType":"actual","enrolled":115,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06712680/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"sichuan-huiyu-pharmaceutical","kind":"company","name":"Sichuan Huiyu Pharmaceutical","route":"/companies/sichuan-huiyu-pharmaceutical/"}]}}